Lee Yong Sup, Seo Seon Hee, Yang Beom-Seok, Lee Jae Yeol
College of Pharmacy, Kyung Hee University, Seoul, Korea.
Arch Pharm (Weinheim). 2005 Oct;338(10):502-5. doi: 10.1002/ardp.200500126.
A series of 7,8-bis(methoxymethyl)-7,8-dihydro-[1,4]dioxino[2,3-g]quinazolines were prepared and evaluated for their inhibition of phosphorylation of the isolated epidermal growth factor receptor (EGFR) enzyme and for their growth inhibition of the A431 cell line. Among them, compound 3c having a 3-iodophenyl ring was most potent (IC(50) = 1.66 nM) against the isolated EGFR enzyme and also showed meaningful potency (GI(50) = 1.99 microM) against the A431 cell line, although less than PD153035 (GI(50) = 1.03 microM). However, compound 3e as the exact rigidified analogue of Erlotinib (Tarceva) was inferior to the original compound when compared to its reported data.
制备了一系列7,8-双(甲氧基甲基)-7,8-二氢-[1,4]二氧杂环辛并[2,3-g]喹唑啉,并对其抑制分离的表皮生长因子受体(EGFR)酶磷酸化的能力以及对A431细胞系的生长抑制能力进行了评估。其中,具有3-碘苯基环的化合物3c对分离的EGFR酶活性最强(IC(50)=1.66 nM),并且对A431细胞系也显示出显著的活性(GI(50)=1.99 microM),尽管不如PD153035(GI(50)=1.03 microM)。然而,与厄洛替尼(特罗凯)结构完全刚性化的类似物化合物3e,与已报道的数据相比,活性不如原化合物。